Newsletter Signup x

Developing our understanding of how bilateral neuroblastoma develops

Neuroblastoma is one of the most common solid tumours affecting children, and remains very difficult to treat. Several studies have already used Next Generation Sequencing (NGS) to examine somatic alterations (the changes in DNA which can happen in the body’s cells which can cause cancer) to try to identify what causes neuroblastoma to form.
NGS has given scientists some amazing ...

Read more

Finding out how neuroblastoma mutates post-chemotherapy to overcome resistance to further treatment

Neuroblastoma is one of the most common solid tumours affecting children, and these days some forms of it are very treatable. But in high risk types, long-term survival rates are only 50%, particularly when a child has had chemotherapy treatment but their cancer has relapsed.
There is evidence to suggest that some chemotherapy treatments actually increase the likelihood of the ...

Read more

Engineering immune cells for the optimal eradication of neuroblastoma

Neuroblastoma is one of the most common solid tumours to occur in children. It can be exceptionally difficult to treat and, despite intensive treatment, around one third of patients cannot currently be cured. In this project, Dr Gilham is harnessing the power of the immune system by engineering specific immune cells to destroy tumour cells. He will lay the essential ...

Read more

Assessment of MIBG therapy in combination with cytotoxic drugs for neuroblastoma

Neuroblastoma, one of the most common childhood cancers, is often not diagnosed until it has spread to other parts of the body. At this stage it is very difficult to treat. A form of radiotherapy known as MIBG therapy has generated long-term remissions but cannot cure advanced disease. Professor Mairs is exploring the use of MIBG therapy in combination with ...

Read more

Blood-based monitoring of treatment response in common childhood cancers

In this project, the team is building on previous work profiling short pieces of genetic code, called microRNAs, in the blood of children being treated for cancer. They are now testing whether measurement of specific microRNAs in blood samples can be used to accurately assess response to treatment in common childhood cancers such as neuroblastoma, Wilms’ tumour and lymphoma.

Read more

Combination treatments for neuroblastoma

Neuroblastoma is one of the most common childhood cancers. It has a high-risk form that is difficult to cure, despite intensive treatment. This project aims to deliver a better understanding of ways to treat this devastating disease.

Read more
Page 1 of 41234